1
|
Ali A, Almalki D, Kotb MA, Alenazi RS. Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City. Neurosciences (Riyadh) 2022; 27:237-243. [PMID: 36252965 PMCID: PMC9749576 DOI: 10.17712/nsj.2022.4.20220038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Accepted: 07/06/2022] [Indexed: 01/01/2023]
Abstract
OBJECTIVES To investigate the distribution of muscle weakness in Myasthenia gravis (MG) and the therapeutic response in each category. METHODS This is a retrospective cross-sectional study included all MG patients presented to our clinic between 2010 and 2020. The demographic, clinical, serological, electrophysiological, radiological, and histopathological data of the patients were recorded. The details of the treatment administered were also documented. Muscle weakness was divided into: ocular, bulbar, and generalized. RESULTS The mean age of the 147 patients included in this study was 34.2±16.6 years. The most common presentation was ocular MG (57.1%). There was no significant association between the gender of the patients and the MG subgroups. Antibodies against AChR were reported in 95.2%, 75%, and 87% of the patients with ocular, bulbar, and generalized myasthenia, respectively. Anti-MuSK antibodies were detected in 20% of the patients with bulbar weakness. Most of the patients with ocular (91.7%) and bulbar (90%) presentation developed generalized weakness. At the end of the follow-up, 82.6%, 70.2%, and 57.5% of the patients with generalized, ocular, and bulbar presentations, respectively demonstrated well-controlled weakness. CONCLUSION The most common initial presentation was ocular weakness. Most patients with ocular and bulbar presentation developed generalized weakness during the follow up period. The most frequently reported autoantibody was against AChR. Most patients with generalized, ocular, and bulbar presentation demonstrated well-controlled weakness at the end of the follow up period.
Collapse
Affiliation(s)
- Abdulrahman Ali
- From the Department of Neurology (Ali, Alenazi), King Fahad Medical City, Riyadh, from the Department of Medicine (Almalki, Kotb), College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia, and from the Department of Neurology (Kotb), Faculty of Medicine, Minia University, Minia, Egypt
| | - Daifallah Almalki
- From the Department of Neurology (Ali, Alenazi), King Fahad Medical City, Riyadh, from the Department of Medicine (Almalki, Kotb), College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia, and from the Department of Neurology (Kotb), Faculty of Medicine, Minia University, Minia, Egypt,Address correspondence and reprint request to: Dr. Daifallah M. Almalki, Department of Medicine, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia. E-mail: ORCID ID: https://orcid.org/0000-0002-9498-6303
| | - Mamdouh A. Kotb
- From the Department of Neurology (Ali, Alenazi), King Fahad Medical City, Riyadh, from the Department of Medicine (Almalki, Kotb), College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia, and from the Department of Neurology (Kotb), Faculty of Medicine, Minia University, Minia, Egypt
| | - Reem S. Alenazi
- From the Department of Neurology (Ali, Alenazi), King Fahad Medical City, Riyadh, from the Department of Medicine (Almalki, Kotb), College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia, and from the Department of Neurology (Kotb), Faculty of Medicine, Minia University, Minia, Egypt
| |
Collapse
|